Placebo (Part 2)

DRUG4 trials

Sponsors

CalciMedica, Inc., Tetherex Pharmaceuticals Corporation, Enanta Pharmaceuticals, Inc, Food and Drug Administration (FDA)

Conditions

AsthmaChronic Hepatitis B Virus InfectionChronic Obstructive Pulmonary DiseaseDrug-induced QT ProlongationPharmacodynamicsPharmacokineticsPneumonia

Phase 1

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

TerminatedNCT04971512

Enanta Pharmaceuticals, IncChronic Hepatitis B Virus Infection

Start: 2021-08-02End: 2021-12-20Updated: 2022-02-14

Electrophysiological Effects of Potential QT Prolonging Drugs

CompletedNCT05716854

Food and Drug Administration (FDA)Drug-induced QT Prolongation, Pharmacodynamics, Pharmacokinetics

Start: 2023-03-21End: 2023-06-13Updated: 2023-06-22

Phase 2

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

CompletedNCT04345614

CalciMedica, Inc.Pneumonia

Start: 2020-04-08End: 2021-07-30Updated: 2026-03-30

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

CompletedNCT04540042

Tetherex Pharmaceuticals CorporationAsthma, Chronic Obstructive Pulmonary Disease

Start: 2020-08-18End: 2022-01-13Updated: 2022-02-02

Related Papers

Inhibition of Calcium Release-Activated Calcium (CRAC) channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE study

American Journal of Nephrology2025-06-091 citations

Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

Critical Care2022-04-0838 citations

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

Critical Care2020-08-14104 citations